Landscapes / Companies
Celgene not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
9 approved
3 in Phase 3
Drugs
15
in active trials · 57 in all
Trials
22 active
170 since 2021
Drugs15
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Bristol Myers Squibb |
Approved | 30 Nov 2026soonPhase 1/2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 30 Nov 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Multiple Myeloma | ||||
| Open drug page | |||||
Thalidomide analog |
Approved | 10 Jan 2027Phase 3 trial completes | |||
| Next date | 10 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM) | ||||
| Open drug page | |||||
Receptor molecules, native or modified |
Approved | 16 Jul 2027Phase 2 trial completes | |||
| How it works | A decoy protein that soaks up a signal molecule before it can reach the body's cells | ||||
| Next date | 16 Jul 2027 · Phase 2 trial completes | ||||
| Also tested for | Myelodysplastic Syndromes, Beta-thalassemia and 7 more | ||||
| Open drug page | |||||
— |
Approved | 16 Nov 2027Phase 3 trial completes | |||
| Next date | 16 Nov 2027 · Phase 3 trial completes | ||||
| Also tested for | Multiple Myeloma, Lymphoma, B-Cell | ||||
| Open drug page | |||||
Nucleoside metabolic inhibitor |
Approved | 31 Jul 2028Phase 2/3 trial completes | |||
| Next date | 31 Jul 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Leukemia, Myeloid, Acute, Acute Myeloid Leukemia and 1 more | ||||
| Open drug page | |||||
Sphingosine 1-phosphate receptor modulator |
Approved | 29 Dec 2028Phase 4 trial completes | |||
| Next date | 29 Dec 2028 · Phase 4 trial completes | ||||
| Also tested for | Colitis, Ulcerative, Relapsing Multiple Sclerosis and 1 more | ||||
| Open drug page | |||||
Isocitrate dehydrogenase 2 inhibitor |
Approved | — | |||
| Also tested for | Leukemia, Myeloid, Acute | ||||
| Open drug page | |||||
Gene therapy substances |
Approved | — | |||
| How it works | A gene therapy | ||||
| Also tested for | Multiple Myeloma | ||||
| Open drug page | |||||
Isocitrate dehydrogenase 1 inhibitor |
Servier Bio-Innovation |
Approved | — | ||
| Also tested for | Leukemia, Myeloid, Acute | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Nov 2026soonPhase 1/2 trial completes | |||
| Next date | 30 Nov 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Multiple Myeloma, Relapsed or Refractory Multiple Myeloma | ||||
| Open drug page | |||||
— |
Phase 3 | 7 Apr 2027Phase 1/2 trial completes | |||
| Next date | 7 Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Lymphoma, Non-Hodgkin, Lymphoma, B-Cell and 6 more | ||||
| Open drug page | |||||
— |
Phase 3 | 12 Sep 2027Phase 3 trial completes | |||
| Next date | 12 Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Metastatic Castration-resistant Prostate Cancer | ||||
| Open drug page | |||||
— |
Phase 2 | 26 May 2027Phase 2 trial completes | |||
| Next date | 26 May 2027 · Phase 2 trial completes | ||||
| Also tested for | Multiple Sclerosis Spasticity, Agitation and 1 more | ||||
| Open drug page | |||||
Gene therapy substances |
Phase 2 | 26 Nov 2027Phase 1/2 trial completes | |||
| How it works | A gene therapy | ||||
| Next date | 26 Nov 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic and 2 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 1 | 1 Aug 2028Phase 1 trial completes | |||
| How it works | An antibody | ||||
| Next date | 1 Aug 2028 · Phase 1 trial completes | ||||
| Also tested for | Multiple Myeloma | ||||
| Open drug page | |||||
No drugs match “”.
About
- No active trial
- 42 other drugs
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021